4,100 Shares in Sanofi (NASDAQ:SNY) Bought by Pinnacle West Asset Management Inc.

Pinnacle West Asset Management Inc. acquired a new position in Sanofi (NASDAQ:SNY) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 4,100 shares of the company’s stock, valued at approximately $236,000.

Other hedge funds have also bought and sold shares of the company. Northwest Investment Counselors LLC bought a new stake in Sanofi during the third quarter valued at about $29,000. POM Investment Strategies LLC purchased a new position in shares of Sanofi in the second quarter valued at about $25,000. Larson Financial Group LLC lifted its position in shares of Sanofi by 480.8% in the first quarter. Larson Financial Group LLC now owns 604 shares of the company’s stock valued at $29,000 after acquiring an additional 500 shares in the last quarter. Register Financial Advisors LLC purchased a new position in shares of Sanofi in the first quarter valued at about $29,000. Finally, Palisade Asset Management LLC purchased a new position in shares of Sanofi in the first quarter valued at about $31,000. Institutional investors own 10.04% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Argus boosted their price objective on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Monday, October 14th. Finally, Citigroup upgraded Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Trading Down 0.5 %

SNY stock traded down $0.26 during midday trading on Thursday, reaching $52.63. 1,173,655 shares of the company traded hands, compared to its average volume of 2,016,314. The firm has a market capitalization of $133.55 billion, a price-to-earnings ratio of 28.80, a P/E/G ratio of 1.40 and a beta of 0.60. The business has a 50 day moving average of $56.12 and a 200-day moving average of $51.67. Sanofi has a 52-week low of $42.63 and a 52-week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last released its earnings results on Thursday, July 25th. The company reported $0.93 EPS for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a return on equity of 26.29% and a net margin of 9.60%. The company’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.95 earnings per share. As a group, sell-side analysts expect that Sanofi will post 4.23 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.